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Based on nineteenth-century findings that showed that heat (fever) could be 
used to treat cancer, local hyperthermia has been developed as a tool to eradicate 
local tumors when surgical excision is deemed impossible. Nonetheless many 
cancer patients with advanced disease still lack effective treatment. During the 
last decades, data has emerged indicating that in situ destruction of tumors in 
some cases may induce tumor antigen release which can stimulate antigen-specific 
cellular immunity. Immune stimulating interstitial laser thermotherapy (imILT) 
is a method for local hyperthermia using laser light to increase tissue temperature 
with a specific protocol which can result in in situ vaccination. In vivo studies have 
shown that the method can induce an immune response that is effective against re-
challenging, therefore indicating abscopal effect. Data was collected during clinical 
studies to assess the safety and feasibility of the method.
Keywords: local hyperthermia, laser ablation, LITT, ILT, imILT, immunooncology, 
laser, abscopal effect, laser ablation, local treatment
1. Introduction
The use of both light and heat in medicine has roots that reside long back in his-
tory. In ancient times, sunlight was used to treat different kinds of skin and mental 
diseases. These treatments mimic, amplify, and in some cases focus on natural 
occurring phenomena to achieve a therapeutic goal.
During the nineteenth century, it was observed that prolonged heating, as fever 
or locally externally induced hyperthermia, could cause cancerous formations to 
disappear [1–4]. Since then, many methods to treat cancer with heat were intro-
duced, from whole body to local methods such as microwave ablation, radiofre-
quency ablation, and laser ablation. The main goals with innovative treatments that 
utilize heat are to give an alternative to patients that are not suitable for surgery and 
minimize the impact of the intervention on the patient. In addition, many of these 
methods have a lower economical impact on the treating institution budget, which 
enables clinics to offer treatment to a larger number of patients.
Other methods that do not make use of heat as treating source were also devel-
oped, such as cryogenic ablation that uses subfreezing temperatures to kill the 
tumor cells or photodynamic therapy (PDT) that uses a selective combination of 
light and photoactivatable drugs to induce radicals in the tumor.
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Interest in focal ablation of tumors increased significantly in the last decades 
because of indications that local treatment may cause shrinkage of untreated, in 
some cases distant, tumors suggesting the involvement of the immune system in the 
process [5–7]. The so-called abscopal effect evoked by local treatments could be used 
to treat patients that lack effective treatments to date. Immune stimulating interstitial 
laser thermotherapy is an innovative hyperthermia treatment that uses a specifically 
tailored treatment protocol based on lower temperature heating for a prolonged 
period of time and designed to maximize the probability of triggering the immune 
system response to the treated tumor type. The medical device system uses laser as 
heat source; the same system is also used for interstitial laser ablation to burn tumor-
ous and non-tumorous formation when imaging is challenging given its natural MR 
compatibility.
2. Laser-induced hyperthermia
Laser-based hyperthermia, known as laser thermotherapy or laser ablation, is a 
focal hyperthermia technique that uses laser light as heat source. Its minimally inva-
sive version for treatment of tumors located deeper in the body is called interstitial 
laser thermotherapy (LITT or ILT). The main goal in oncological treatments is to 
achieve tumor destruction without damaging tissue and structures surrounding the 
neoplastic lesion to be treated. Different factors concur to the tissue destruction, 
among these direct cell death and coagulation.
During laser-induced thermotherapy, light causes damage in tissue due to 
absorption of light and through heat conduction into the tissue of the absorbed 
energy. Laser thermotherapy therefore produces a lesion that is larger than the 
volume where light is absorbed due to this heat conduction.
These two phenomena, direct light absorption and heat conduction, determine 
the modality and the parameters to be used to control the tumor heating and are 
dependent on the characteristics of the tissue to be treated.
2.1 Direct tissue absorption
The penetration depth, which is defined as the distance at which the light is 
attenuated to 1/e (37% of original intensity), can be used to describe the volume 
in which the main part of the laser energy is absorbed in tissue, i.e., where direct 
absorption is the dominant factor. Penetration depth can also be used to deter-
mine whether the possibility for carbonization during ablation is affected by, for 
example, the choice of the wavelength. Low penetration depth indicates a higher 
power density in tissue and thereby a higher risk of carbonization. Therefore 
it is an important factor to be taken into consideration both when designing 
the optical fibers to deliver the light and when deciding on suitable treatment 
parameters.
Penetration depth depends on the tissue type since the optical properties are 
dependent on tissue composition and structure. For a generic tissue composition, 
the effective attenuation coefficient and the penetration depth can be calculated as 
follows:
  μ eff =  √ 
_______________
  3  μ a ( μ a +  μ s (1 − g) ) (1)
  δ eff =  1 ⁄ μ eff  (2)
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Values for μa, μs, and g, in different tissue types, are available in textbooks deal-
ing with optical properties in tissue, e.g., [8].
The absorption, μa, of a specific tissue depends on the tissue composition. Each 
component has a specific absorption spectrum. Biological tissue has a relatively low 
absorption in the interval 600–1200 nm. This is due to the fact that the absorption 
spectrum of the main component of tissues, water, has a minimum in this region. 
Other tissue components, especially blood, must also be considered. In Figure 1, 
only the major absorbers for the specific wavelength in use are shown.
The scattering, μs, depends on the tissue structure, for example, on the cell size 
and shape, and how they are arranged in the tissue. Light scattering in tissue has 
two contributions, Rayleigh and Mie scattering; the latter is usually predominant 
due to the scattering of particle size. The scattering is inversely proportional to the 
wavelength: as the wavelength increases, the scattering coefficient diminishes. As 
the two wavelengths considered are spectrally close, the scattering coefficients are 
similar. The scattering spectrum for a generic soft tissue is shown in Figure 2 and 
was calculated according to [9]:
  (3)
The equation takes into consideration different scattering contributions mainly 
due to the different sizes of the scattering centers.
All the parameters are tissue dependent. The values for a generic soft tissue in 
Table 1 were used in Figure 2.
2.2 Heat conduction in biological tissue
The energy deposited in tissue causes an increase in temperature in the portion 
of tissue where laser light is absorbed. Naturally, the difference in heat evens out 
over time. The heat is removed from the volume where absorption of light occurs by 
active or passive cooling. Active cooling is achieved through blood perfusion, which 
varies during time according to response of the tissue to heat and is dependent on 
the perfusion rate and therefore on the tissue type. Passive cooling is due to heat 
Figure 1. 
Absorption spectra of tissue components in the window 500–1100 nm. Dotted line at 1064 nm.
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conduction and is described by the second law of thermodynamics which asserts 
that heat flows spontaneously from hot to cold bodies, in this case from the heated 
portion of tissue to the portion of tissue at body temperature.
If the delivered energy is high enough, the heat conduction concurs to the 
progression of the damage since heat conduction can cause tissue temperatures to 
rise well above the threshold for permanent damage. The threshold for permanent 
tissue damage is discussed in the following paragraphs.
Pennes’ equation models heat distribution in the tissue:
  (4)
The equation describes the heat flow in the tissue as the combination of 
(passive) heat conduction, (active) heat transport due to blood perfusion and 
dependent on the temperature difference, metabolic heat source which is the heat 
produced by the tissue itself, and the external heat source, in this case the laser 
energy [10–12].
2.3 Laser-induced tissue effects
Effects on biological tissues induced by lasers can vary in nature and can be 
classified in several groups among which are photochemical damage, when light 
triggers a chemical reaction in the tissue, and thermal effects, when heat is the 
cause of the outcome. Photochemical damage includes radical formation and tissue 
inflammation, while examples of thermal damage are protein denaturation and 
burning. The type of damage triggered depends mainly on the characteristics of the 
Figure 2. 







Scattering parameters for a generic tissue [9].
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light beam (wavelength, power, pulse properties, exposure time, spot size) and if 
the beam is collimated, i.e., laser source.
Thermal effects are caused when the temperature in the tissue is locally 
increased over the physiological temperature; the threshold is generally set to 
40°C. Conditional to the specific tissue properties, beam characteristics and expo-
sure times, the tissue can undergo hyperthermia (<60°C), coagulation, vaporiza-
tion, carbonization, or pyrolysis. Hyperthermia can be reversible or irreversible 
depending on the combination of temperature reached and exposure time. Local 
ablation techniques, such as microwave, radiofrequency, or laser ablation, aim at 
achieving a temperature of at least 60°C in the whole treated volume, therefore 
inducing cell death by coagulation; vaporization and carbonization may occur.
3.  Laser ablation and immune stimulating interstitial laser 
thermotherapy (imILT)
Classic laser ablation is used to treat solid tumor masses in a variety of organs 
and aims at heating the whole tumor volume at a temperature of at least 60°C in 
order to coagulate the tissue in the area to be treated. In this way, near to instant cell 
death is achieved. An optical fiber is placed in the center of the region of inter-
est, and light is delivered for a period of time of 1–10 minutes depending on the 
volume to ablate and the device used. The treatment can be repeated directly after 
to achieve larger coagulation volume either inserting the fiber in a new position or 
utilizing the so-called pull-back technique, meaning performing a new ablation 
along the insertion track by pulling the fiber back.
Immune stimulating interstitial laser thermotherapy (imILT) is a local abla-
tion method that works at non-coagulating temperatures at the tumor border. The 
technique consists in creating a temperature gradient in the tumor that results in a 
heating to 46°C at the tumor border or some millimeters outside it. The tempera-
ture is then kept for a prolonged period of approximately 30 minutes to achieve an 
immunogenic cell death (ICD) at the tumor border, visible only 48–72 hours after 
treatment, which activates an immune response [13, 14]. An example of ablation 
achieved performing an imILT treatment is shown in Figure 3. The biological 
process is not fully understood to date, but the hypothesis is that imILT creates 
inflammation in the tumor. Damage-associated molecular pattern (DAMP) signal 
is created, and antigens, which are not coagulated due to the low temperatures, are 
released [7, 15–17]. The antigens are picked up by antigen-presenting cells (APCs) 
that in turn trigger an immune response [18–21].
The method can in principle be used to treat all types of solid tumors, but some 
types will be more responsive than others depending on the tumor biology, which is 
true for immunotherapies in general. Some results from proof-of-concept preclini-
cal and clinical studies are presented in this chapter.
3.1 Technical solutions for interstitial laser thermotherapy
The CE-marked and FDA-approved TRANBERG® Thermal Therapy System for 
imILT consists of three main parts: a laser generator, a laser applicator, and a ther-
mometry system. The laser generator is a diode-based system that emits light at a 
wavelength of 1064 nm and with a maximum accessible power of 25 W continuous 
wave. The unit has a built-in temperature feedback system that is able to measure 
the temperature in the tissue by means of a minimally invasive temperature probe 
and to drive the laser emission in order to maintain a stable temperature, set by 
the user between 43 and 50°C, for a treatment time of up to 30 minutes. The laser 
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applicator consists of a non-cooled optical fiber and an introducer to enable inser-
tion of the fiber in the tissue. The non-cooled optical fiber is available in different 
tip designs tailored to the ablation volume and shape to be achieved and the tissue to 
be treated.
All the procedures are performed under image guidance, using MRI, ultrasound, 
computed tomography (CT), or a combination of the previous depending on the 
availability of these techniques at the clinic. While it is only possible to perform 
imILT treatments using ultrasound or CT guidance due to limitations in the temper-
ature probe design, the design of the laser applicator allows laser ablation procedure 
to be performed with MRI guidance, for example, when performing a focused 
laser ablation (FLA) for the treatment of early prostate cancer or benign prostatic 
hyperplasia (BPH).
3.2 In vivo studies on abscopal effect of imILT
Extensive preclinical studies were performed to prove the immune stimulating 
effects of imILT. One specific study aimed at comparing the immunologic memory 
evoked by imILT if compared to resection [22].
Research was conducted on 280 rats divided in four groups: (1) rats with tumor 
implanted in the liver that were treated with imILT, (2) rats with tumors implanted 
in the liver that were treated with surgical resection, (3) rats without tumor that 
were treated with imILT ablating normal liver tissue (sham imILT), and (4) rats 
without tumors that were treated with resection of a part of a healthy liver (sham 
resection).
Figure 3. 
Effect of imILT treatment on porcine healthy skeletal muscle tissue. Coagulation is achieved within the yellow 
circle, and immunogenic cell death (ICD) is achieved along the ablation border, between the yellow and the 
blue line.
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Rats in groups 1 and 2 were implanted with adenocarcinoma and treated after 
6–8 days. A second challenging tumor of the same kind was implanted in another 
lobe 2, 5, or 10 weeks later, and the animals were followed for up to 48 days after 
rechallenge unless they showed signs of inactivity or distress earlier. Vital tumor at 
sacrifice was evaluated together with other immune system markers. Group 1, tumor 
treated with imILT, showed a distinct behavior if compared with the other three 
groups. In groups 2, 3, and 4, the challenging tumor, second implanted, displayed a 
growth so substantial that none of the rats survived for 48 days. On the contrary, rats 
in group 1 showed eradication of the challenging tumor at day 48. The extent of the 
tumor burden for the four groups is represented in Figure 4. These findings, com-
bined with results from immunology markers from blood tests, indicate that imILT 
invokes a strong immune response and an immunologic memory against the treated 
cancer.
3.3 Clinical results
A number of pre-marketing clinical studies on imILT were performed at Lund 
University Hospital, Lund, Sweden, where the method was developed for the first 
time. These studies demonstrated the recruitment of immunocompetent cells in 
breast cancer patients which indicate a favorable antitumor activity [23–27].
More recently, initial findings from the clinical study program designed 
to evaluate the safety and the usability of the method performed using the 
TRANBERG®|Thermal Therapy System (Clinical Laserthermia Systems, AB, 
Sweden) were published [28]. A variety of solid tumors are included in the study 
program; the data was reported after 12 patients were treated, out of which 4 were 
female and 8 were male. Indications treated were breast cancer (n = 1), breast 
cancer metastasis (n = 1), colon cancer metastasis (n = 2), malignant melanoma 
metastasis (n = 2), pancreatic carcinoma (n = 1), and primary pancreatic carcinoma 
(n = 5); the latter two were treated in open surgery, while the other percutaneously. 
All the treatments were performed using CT or ultrasound guidance. All patients 
included in the study underwent numerous previous treatments due to comorbidity. 
Figure 4. 
Tumor burden after implantation of challenging tumor. Only rats having been treated with imILT of primary 
tumor survived for 48 days after implantation of challenging tumor. All other rats in the 48-day study group 
had to be euthanized within 10–30 days after the tumor challenge due to extensive tumor. Image: Mats Ekelund.
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Immunotherapy was delivered on two malignant melanoma patients before imILT 
treatment but not during the study period.
One serious adverse event was reported out of nine patients within the spon-
sor initiated clinical study; the frequency of serious adverse events is in line with 
previous data on other local ablative techniques, including laser ablation [29, 30], 
indicating that the procedure can be safely performed.
Usability results vary among the different study clinics. Preliminary indications 
suggest that insertion and placement of the instrumentation within the volume to 
be treated are the main challenge, while sterile access, removal from the tissue, and 
handling of disposable are perceived as less complicated. Handling of the laser unit 
needs further investigation as the data is spread [28].
The safety studies were not designed to collect statistically significant efficacy 
results. Each study included different indications to gather safety data and input to 
future efficacy studies as extensive as possible leading to a low number of patients 
per indication, and therefore no indication-based data was published. Future 
ongoing publications will include indicative efficacy and quality-of-life results from 
these studies.
3.3.1 Case report
This case is a 53-year-old patient with pancreatic cancer diagnosed about 2 years 
before and treated with first-line chemotherapy, FOLFIRINOX 16 cycles, for tumor 
reduction. Disease progression was registered after 12 cycles. Due to intolerable toxic-
ity, the treatment regimen was changed to second- and third-line chemotherapies, 
gemcitabine and protein-bound paclitaxel 16 cycles, after which partial response 
was achieved. At the time of the first imILT treatment 2 years after the diagnosis, the 
patient presented with pancreatic carcinoma and three liver metastases (stage IV). 
PET-CT showed a hypermetabolic focus around the biliary stent, but no clearly visible 
tumor in the pancreas, and three metastases in the liver (segments VI, V/VI, and V/
peri-gallbladder area).
The first treatment was performed on a 19 mm liver metastasis in segment VI 
that was metabolically active; see Figure 5. The intervention was performed percu-
taneously under CT guidance, and a first treatment was performed by placing the 
tip of the radial laser applicator in the metastasis—see Figure 6—and a temperature 
Figure 5. 
PET-CT (left) and CT (right) scans showing the position of the treated metastasis during the first treatment 
session [31].
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needle at a distance of approximately 10 mm. The temperature needle was used to 
regulate the laser emission based on the measured temperature and achieve ICD in 
a region of the lesion that presented as metabolically active from the PET scan. A 
temperature of 44–45°C was kept during a period of 30 minutes according to the 
imILT protocol. A second overlapping ablation was performed after repositioning 
the laser applicator to necrotize the whole volume of the metastasis. Track ablation 
was performed to minimize risk for track seeding of tumor cells along the inser-
tion track. A post-procedure CT scan was performed to ensure the ablation of the 
entire tumor, which was achieved as shown in Figure 7 (black arrow). The patient 
suffered slight pain and rise in temperature (38°C) posttreatment, but no other 
Figure 6. 
Laser applicator positioning visualized using CT scan while placing the instrumentation for the first 
treatment [31].
Figure 7. 
Posttreatment CT that shows the ablation cavity (black arrow) and the biliary stent (white arrow). First 
treatment session [31].
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discomfort was registered; the patient was discharged after 3 days. No complica-
tions were reported during the first 3 months following therapy [31].
Partial response in liver metastasis and total response in pancreas primary tumor 
were registered 21 months later. However, 3 months later disease progression was 
noticed, and the patient was treated with imILT for a second time 24 months after 
the initial treatment. The targeted metastasis was a 35 × 50 mm liver metastasis 
evaluated at ultrasound at the time of the treatment. The metastasis was treated 
performing one imILT treatment combined with an overlapping LITT treatment of 
about 5 minutes to necrotize the whole metastatic mass; the imILT treatment was 
achieved positioning the radial laser applicator off center within the tumor and the 
temperature probe at a distance of approximately 11 mm from the applicator. The 
temperature measured by the probe was kept at 43–45°C for 20 minutes.
Lastly, a third imILT treatment was performed after 40 months from the first 
treatment because of new disease progression. A new 20 mm liver metastasis was 
treated using a diffuser laser applicator combined with an introducer with built-in 
temperature sensors, which resulted in only one puncture. The laser applica-
tor was inserted in the center of the metastasis, and the sensors were positioned 
25 mm from the applicator tip to achieve a lesion of 25–30 mm in diameter. To date, 
4 months after the last treatment, no complications connected to the laser treat-
ment have been reported [32].
4. Conclusion
Local ablation of tumors is receiving increasing attention for the treatment of 
metastatic disease because of observed effects on distant tumorous masses suggest-
ing the involvement of the immune system following local therapy.
One technique for local tumor eradication is laser ablation which kills the tumor 
mass by heating the tissue through direct light absorption and heat transfer result-
ing in tissue coagulation. imILT is an interstitial laser ablation method tailored 
to evoke an immune response against the treated tumor. The technique utilizes a 
laser applicator to deliver energy in the form of laser light to the tissue; the energy 
delivered to the tissue is precisely controlled based on the temperature measured 
by a sensor inserted in the tissue at the periphery of the tumor to obtain a lower 
temperature ablation that aims at maximizing the immune cell death (ICD) volume 
of the ablation.
Preclinical results indicate that imILT invokes an immune response against the 
treated tumor, if compared with resection in a rat tumor model. Clinical studies 
suggest that the procedure can be safely performed since the frequency of the 
adverse events is in line with previous data on other local ablation techniques. The 
case of a pancreatic cancer patient treated with imILT was presented.
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Tb-T difference between the heated tissue and the blood or the sur-
rounding tissue
Q met metabolic heat
Q ext external heat sources
BPH benign prostate hyperplasia
DAMP damage associated molecular pattern
CT computed tomography
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ILT interstitial laser thermotherapy
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